Studies on the procurement of blood coagulation factor VIII. In vivo studies on blood components prepared in half-strength citrate anticoagulant.
To determine the viability of blood cells collected in half-strength (0.5 CPD.A2) and full-strength citrate anticoagulants, paired crossover autologous survival studies were performed in normal volunteers using 51Cr-labelled red cells after 35 days storage and 111In-labelled platelets after 5 days storage. For both studies, viability was better maintained in 0.5 CPD.A2 anticoagulant. This was significant for red cells (24-hour survival: 80 +/- 6 vs. 52 +/- 21%) but not for platelets by either linear or multiple-hit models (recovery 51 +/- 13 vs. 38 +/- 14%, survival 5.1 +/- 1.4 vs. 3.7 +/- 1.5 days). The poor viability of red cells after storage in full-strength anticoagulant was associated with low cellular adenosine triphosphate levels and was confirmed in follow-up studies.
D000225:Adenine; D000925:Anticoagulants; D001792:Blood Platelets / Q000166:cytology; D001804:Blood Transfusion, Autologous; D002470:Cell Survival; D002951:Citrates; D004905:Erythrocyte Aging; D017707:Erythrocyte Transfusion; D005169:Factor VIII; D005947:Glucose; D006801:Humans; D010710:Phosphates
D000925:Anticoagulants; C034876:CPDA solutions; D002951:Citrates; D010710:Phosphates; D005169:Factor VIII; D005947:Glucose; D000225:Adenine